Nkarta has added further patents advancing an immuno-oncological approach honed by scientific founder Dario Campana.

Nkarta Therapeutics, a US-based cellular therapy developer based on research from National University of Singapore and St Jude Children’s Research Hospital, licensed additional immuno-oncological patents from the same two institutions on Monday.

The licence relates to approaches for engineering chimeric receptors for natural killer cells while also stimulating the cells’ production. Chimeric antigen receptor cell therapy (Car-T) exploits chimeric receptors to direct immune system bodies such as natural killer cells in fighting cancerous blood malignancies.

Founded in 2015, Nkarta Therapeutics…